Alkermes moves alcohol dependency drug candidate to Phase 2 study

By Mass High Tech staff

Video Gallery

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Researchers focus on macular degeneration

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

Alkermes Inc. has begun a Phase 2 clinical study of ALKS 33, the Cambridge biotech’s drug candidate for treating alcohol dependence and other central nervous system disorders. The study is expected to determine safety and efficacy of multiple doses of the oral opioid modulator.

Alkermes (Nasdaq: ALKS) will test up to 440 patients for 12 weeks through random distribution of the drug candidate and a placebo. The company will determine the efficacy by evaluating patients that have refrained from heavy alcohol use during the eight-week evaluation phase.

The company announced Monday that it plans to seek approval next year to market its Vivitrol drug to treat opioid dependence, based on the results of a clinical trial.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.